TB MONITORING ADHERENCE AND TREATMENT ENDPOINTS PROJECT: - Trial PACTR201902681157721
Access comprehensive clinical trial information for PACTR201902681157721 through Pure Global AI's free database. This Not Applicable trial is sponsored by Bill and Melinda Gates Foundation ; South African Medical Research Council; Stop TB Partnership TB REACH and is currently Recruitment Completed. The study focuses on Infections and Infestations.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to Pan Africa Clinical Trials Registry data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Bill and Melinda Gates Foundation ; South African Medical Research Council; Stop TB Partnership TB REACH
Stop TB Partnership TB REACH; South African Medical Research Council; Bill and Melinda Gates Foundation
Timeline & Enrollment
Not Applicable
Jan 01, 1900
Jan 01, 1900
Summary
Background: South Africa, the country with the highest TB incidence (781/100,000 population), reported treatment success rates of 81% among new and retreatment patients, 80% among HIV-positive TB patients and 54% among patients with rifampicin resistance. A South African TB Consortium was recently established to test innovations to reduce gaps in the TB care cascade and to accelerate the demonstration to scale processes. This proof of concept project, proposed by the consortium, and supported by the MRC South Africa, aims to implement and evaluate an adherence monitoring system (using the Wisepill evriMED device) with a differentiated response to patient care, among drug-sensitive TB (DS-TB) patients in three provinces of South Africa.Aims: This study aims to implement and evaluate the use of an adherence monitoring system (using the Wisepill evriMEDdevice) with a differentiated response to patient care, among drug-sensitive TB patients in three provinces of South Africa. Primary Objective:i) To evaluate whether implementation of the Wisepill evriMEDdevice with real-time monitoring and differentiated care is able to increase the proportion of patients with >90% adherence to DS-TB treatment
ICD-10 Classifications
Data Source
Pan Africa Clinical Trials Registry
PACTR201902681157721
Device Trial